Surrozen Operating Inc

Surrozen Operating Inc, commonly known as Surrozen, is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2015, the company became publicly traded on NASDAQ under the ticker symbol "SRZN" on August 12, 2021. As of December 31, 2025, Surrozen had 44 employees. The company's market capitalization was approximately $306 million as of May 22, 2026, with a trailing 12-month revenue of $7.49 million as of March 31, 2026.

Surrozen focuses on discovering and developing drug candidates to selectively modulate the Wnt pathway, a crucial mediator of tissue repair, across various organs and tissues. The company utilizes its Wnt biology expertise and antibody-engineering platform to develop multifunctional biologics. Surrozen has recently shifted its primary research and development efforts to ophthalmology, with a focus on treatments for severe eye conditions. Its pipeline includes product candidates such as SZN-8141 and SZN-8143 for wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and other retinopathies, and SZN-413 for retinal vascular associated diseases, which is licensed to Boehringer Ingelheim.

Surrozen Operating Inc's patent litigation posture is that of an operating company defending its intellectual property. The company has been involved in one tracked case, appearing as a defendant in a proceeding before the Patent Trial and Appeal Board (PTAB): Unified Patents v. Surrozen Operating Inc. This indicates that Surrozen is a target of patent challenges rather than an entity primarily asserting patents against others. Unified Patents is known for its role in challenging patents asserted by Non-Practicing Entities (NPEs) or in cases where its members are accused of infringement.